Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes.

ABSTRACT:

Aims

To compare the risk of gastrointestinal adverse events in new users of glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose cotransporter-2 inhibitors (SGLT2i) and insulin glargine.

Materials and methods

We conducted an active comparator, new user design study in veterans with type 2 diabetes who initiated one of these drug classes between 1 January 2018 and 31 December 2021 (N = 141 080). Inverse probability weighted Cox regression models were used to relate drug class to outcomes of gastroparesis, intestinal obstruction, gallstones, acute cholecystitis, acute pancreatitis and all-cause death.

Results

There were 19 765 (14.0%) veterans initiated on GLP-1RA, 75 058 (53.2%) on SGLT2i and 46 257 (32.8%) on insulin glargine. Compared to SGLT2i, GLP-1R

SUBMITTER: Sarwal A 

PROVIDER: S-EPMC12409243 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature